Clinical Trial: Remimazolam vs Propofol for Motor and Somatosensory Evoked Potentials in Spinal Tumor Surgery

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07901504) titled 'Remimazolam vs Propofol for Motor and Somatosensory Evoked Potentials in Spinal Tumor Surgery' on Oct. 21.

Brief Summary: Intraoperative neurophysiological monitoring (IONM) using motor evoked potentials (MEP) and somatosensory evoked potentials (SEP) is routinely applied during spinal tumor resection to detect impending neurological injury. Propofol-based total intravenous anesthesia suppresses MEP amplitude in a dose-dependent manner, which can generate false-positive alerts and complicate interpretation of IONM signals. Remimazolam is an ultra-short-acting benzodiazepine whose effect on evoked potentials during spine surgery has ...